// App-Quantinova.ai

4982 : BNC105 induces tumor micro-environment changes which enhance the efficacy of checkpoint inhibitor therapy in preclinical models

Researchers

Presenter

  • Daniel J. Inglis

Principal Investigators

  • Donna M. Beaumont

  • Annabell F. Leske

  • Michaela A. Scherer

  • Tina C. Lavranos

Medical Centers

  • Bionomics Ltd., Thebarton, Australia.

Locations

  • Australia

Companies

  • Bionomics Ltd.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Chronic Lymphocytic Leukemia

  • Solid malignancies

Biomarkers

  • N/A

Drug/Treatment

  • BNC-105

Outcome

  • N/A

Study Design

  • N/A

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved